Filtered By:
Source: Clinical Cancer Research
This page shows you your search results in order of date. This is page number 7.
Order by Relevance | Date
Total 104 results found since Jan 2013.
Targeted Nanomedicine for Suppression of CD44 and Simultaneous Cell Death Induction in Ovarian Cancer: an Optimal Delivery of siRNA and Anticancer Drug.
CONCLUSION: We show a high therapeutic potential for combinatorial treatment of ovarian carcinoma with a novel drug delivery system that effectively transports siRNA targeting to CD44 mRNA simultaneously with cytotoxic agents.
PMID: 24036854 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - September 13, 2013 Category: Cancer & Oncology Authors: Shah V, Taratula O, G OB, Taratula OR, Rodriguez-Rodriguez L, Minko T Tags: Clin Cancer Res Source Type: research
Targeting Protein Kinase CK2 Suppresses Pro-survival Signaling Pathways and Growth of Glioblastoma.
CONCLUSIONS: CK2 inhibitors may be considered for treatment of patients with GBM.
PMID: 24036851 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - September 13, 2013 Category: Cancer & Oncology Authors: Zheng Y, McFarland BC, Drygin D, Yu H, Bellis SL, Kim H, Bredel M, Benveniste EN Tags: Clin Cancer Res Source Type: research
Network analysis identifies an HSP90-central hub susceptible in ovarian cancer.
CONCLUSION: These results strongly support investigation of ganetespib, a single-targeted agent with effects on numerous proteins and pathways, in augmenting standard EOC therapies.
PMID: 23900136 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - July 30, 2013 Category: Cancer & Oncology Authors: Liu H, Xiao F, Serebriiskii IG, O'Brien SW, Maglaty MA, Astsaturov IA, Martin L, Litwin S, Proia DA, Golemis EA, Connolly DC Tags: Clin Cancer Res Source Type: research
Estrogen Receptor Alpha regulates ATM expression through miRNAs in breast cancer.
CONCLUSIONS: We reveal a novel mechanism involving ERα and miRNA 18a and 106a regulation of ATM in breast cancer.
PMID: 23857602 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - July 15, 2013 Category: Cancer & Oncology Authors: Guo X, Yang C, Qian X, Lei T, Li Y, Shen H, Fu L, Xu B Tags: Clin Cancer Res Source Type: research
Inhibition of protein phosphatase 2A radiosensitizes pancreatic cancers by modulating CDC25C/CDK1 and homologous recombination repair.
CONCLUSIONS: Collectively, our data demonstrate that PP2A inhibition radiosensitizes pancreatic cancer both in vitro and in vivo via activation of CDC25C/CDK1 and inhibition of HRR, and provide proof-of-concept evidence that PP2A is a promising target for the improvement of local therapy in pancreatic cancer.
PMID: 23780887 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - June 18, 2013 Category: Cancer & Oncology Authors: Wei D, Parsels L, Karnak D, Davis M, Parsels J, Zhao LL, Maybaum J, Lawrence T, Sun Y, Morgan MA Tags: Clin Cancer Res Source Type: research
RRM2 Regulates Bcl-2 in Head and Neck and Lung Cancers: A Potential Target for Cancer Therapy.
CONCLUSIONS: Our novel findings add to the knowledge of RRM2 in regulating expression of the anti-apoptotic protein Bcl-2 and reveal a critical link between RRM2 and Bcl-2 in apoptosis signaling.
PMID: 23719266 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - May 29, 2013 Category: Cancer & Oncology Authors: Rahman MA, Amin AR, Wang D, Koenig L, Nannapaneni S, Chen Z, Wang Z, Sica GL, Deng X, Chen ZG, Shin DM Tags: Clin Cancer Res Source Type: research
Enhancing chemotherapy response with sustained EphA2 silencing using multistage vector delivery.
CONCLUSIONS: These findings indicate that MSV/EphA2 merits further development as a novel therapeutic agent for ovarian cancer.
PMID: 23386691 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - February 5, 2013 Category: Cancer & Oncology Authors: Shen H, Rodriguez-Aguayo C, Xu R, Gonzalez-Villasana V, Mai J, Huang Y, Zhang GD, Guo X, Bao L, Guoting Q, Deng X, Li Q, Erm D, Sakamoto JH, Liu X, Chavez-Reyes A, Han HD, Sood AK, Ferrari M, Lopez-Berestein G Tags: Clin Cancer Res Source Type: research
SHP2 Is Overexpressed and Inhibits pSTAT1-Mediated APM Component Expression, T-cell Attracting Chemokine Secretion, and CTL Recognition in Head and Neck Cancer Cells.
CONCLUSION: These findings suggest for the first time an important role for SHP2 in APM-mediated escape of HNC cells from CTL recognition. Targeting SHP2 could enhance T-cell-based cancer immunotherapy. Clin Cancer Res; 19(4); 1-11. ©2012 AACR.
PMID: 23363816 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - January 31, 2013 Category: Cancer & Oncology Authors: Leibowitz MS, Srivastava RM, Andrade Filho PA, Egloff AM, Wang L, Seethala RR, Ferrone S, Ferris RL Tags: Clin Cancer Res Source Type: research
Functional analysis of genes in regions commonly amplified in high-grade serous and endometrioid ovarian cancer.
CONCLUSIONS: By taking this integrative approach to target discovery we have streamlined the translation of high-resolution genomic data into pre-clinical in vitro studies, resulting in the identification of a number of genes that may be specifically targeted for the treatment of ovarian tumors.
PMID: 23362323 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - January 29, 2013 Category: Cancer & Oncology Authors: Davis SJ, Sheppard KE, Pearson RB, Campbell IG, Gorringe KL, Simpson K Tags: Clin Cancer Res Source Type: research
Lactate Dehydrogenase B is required for the growth of KRAS-dependent lung adenocarcinomas.
CONCLUSION: This study identifies LDHB as a regulator of cell growth in a subset of lung adenocarcinoma and may provide a novel therapeutic approach for treating lung cancer.
PMID: 23224736 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - December 26, 2012 Category: Cancer & Oncology Authors: McCleland ML, Adler AS, Deming L, Cosino E, Lee LB, Blackwood EM, Solon M, Tao J, Li L, Shames DS, Jackson EL, Forrest W, Firestein R Tags: Clin Cancer Res Source Type: research
Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents.
CONCLUSIONS: We demonstrate that activation of the PI3K/AKT pathway is a mechanism of both innate and acquired resistance to BRAF inhibitors in BRAFV600E CRC, and suggest combinatorial approaches to improve outcomes in this poor prognosis subset of patients.
PMID: 23251002 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - December 18, 2012 Category: Cancer & Oncology Authors: Mao M, Tian F, Mariadason JM, Tsao L, Lemos R, Dayyani F, Yennu Nanda VG, Jiang ZQ, Wistuba I, Tang X, Bornmann WG, Bollag G, Mills GB, Powis G, Desai J, Gallick GE, Davies MA, Kopetz S Tags: Clin Cancer Res Source Type: research
Sorafenib inhibits cell migration and stroma-mediated bortezomib resistance by interfering B-cell receptor signaling and protein translation in mantle cell lymphoma.
CONCLUSIONS: We demonstrate for the first time that sorafenib interferes BCR signaling, protein translation and modulates the microenvironment prosurvival signals in MCL, suggesting that sorafenib, alone or in combination with bortezomib, may represent a promising approach to treat MCL patients.
PMID: 23231952 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - December 11, 2012 Category: Cancer & Oncology Authors: Xargay-Torrent S, Lopez-Guerra M, Montraveta A, Saborit-Villarroya I, Rosich L, Navarro A, Perez-Galan P, Roue G, Campo E, Colomer D Tags: Clin Cancer Res Source Type: research
Integration of cell line and clinical trial genome-wide analyses supports a polygenic architecture of paclitaxel-induced sensory peripheral neuropathy.
CONCLUSIONS: The enrichment results and functional example imply that cellular models of chemotherapeutic toxicity may capture components of the underlying polygenic architecture of related traits in patients.
PMID: 23204130 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - November 30, 2012 Category: Cancer & Oncology Authors: Wheeler HE, Gamazon ER, Wing C, Njiaju UO, Njoku C, Baldwin RM, Owzar K, Jiang C, Watson D, Shterev I, Kubo M, Zembutsu H, Winer EP, Hudis CA, Shulman L, Nakamura Y, Ratain MJ, Kroetz D, Cox NJ, Dolan ME Tags: Clin Cancer Res Source Type: research
Dysregulation of the repressive H3K27 trimethylation mark in head and neck squamous cell carcinoma contributes to dysregulated squamous differentiation.
CONCLUSIONS: Collectively, these data suggest that aberrant differentiation in HNSCC may be attributed to epigenetic dysregulation and suggests that inhibition of PRC2-mediated gene repression may represent a potential therapeutic target.
PMID: 23186778 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - November 27, 2012 Category: Cancer & Oncology Authors: Gannon O, Endo-Munoz LB, Merida de Long L, Hazar-Rethinam M, Saunders NA Tags: Clin Cancer Res Source Type: research
